Logo_arpbig_fondo_transparente_colores_blanco_letras_blanco
2025
Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa.
By fernando | |
Sastre-Femenia MÀ; Gomis-Font MA; Oliver A Abstract: A growing number…
Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?
By fernando | |
Pina-Sánchez M; Rua M; López-Causapé C; Bilbao I; Sastre-Femenia MÀ;…
Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosa.
By fernando | |
Oliver A; Arca-Suárez J; Gomis-Font MA; González-Pinto L; López-Causapé C…
Comparative analysis of acute respiratory infections of viral etiology in children under 6 months with and without nirsevimab in the Balearic Islands (2022-2023 and 2023-2024).
By fernando | |
Reina J; Iturbe A; Viana-Ramírez J; Sbert G; Carrasco J;…
Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model.
By fernando | |
Montero MM; Domene-Ochoa S; Prim N; Ferola E; López-Causapé C;…
1 2